首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cxcl11 |
| Uniprot No | O14625 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-94aa |
| 氨基酸序列 | FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKG QRCLNPKSKQARLIIKKVERKNF |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL11重组蛋白的3篇参考文献示例(注：内容为模拟概括，实际文献请通过学术数据库查询)：
1. **文献名称**：CXCL11 Recombinant Protein Enhances T Cell Migration in Autoimmune Models
**作者**：Smith A, et al.
**摘要**：该研究利用大肠杆菌表达系统制备了重组CXCL11蛋白，证实其能有效促进CD4+ T细胞趋化，并在实验性自身免疫性脑脊髓炎(EAE)模型中抑制炎症细胞浸润。
2. **文献名称**：Antitumor Activity of Recombinant CXCL11 through NK Cell Activation
**作者**：Zhang Y, et al.
**摘要**：通过哺乳动物细胞表达的重组CXCL11蛋白在黑色素瘤模型中显示出抗肿瘤效果，机制研究揭示其通过激活NK细胞的IFN-γ分泌及增强肿瘤组织淋巴细胞浸润发挥作用。
3. **文献名称**：CXCL11-IgG Fusion Protein Engineering for Chronic Infection Therapy
**作者**：Lee JH, et al.
**摘要**：研究者构建了CXCL11与IgG Fc段的融合蛋白，证实其半衰期延长了3倍，在慢性病毒感染小鼠模型中显著提高了病毒特异性T细胞向感染部位的募集效率。
(提示：实际文献需通过PubMed/Google Scholar检索关键词“recombinant CXCL11”、“CXCL11 protein function”获取)
CXC chemokine ligand 11 (CXCL11), a member of the CXC chemokine subfamily, is a small cytokine encoded by the *CXCL11* gene in humans. It is primarily induced by interferon (IFN)-γ and IFN-β, playing a pivotal role in immune responses by recruiting activated T cells and natural killer (NK) cells via interaction with the G protein-coupled receptor CXCR3. Structurally, CXCL11 shares homology with other IFN-inducible chemokines like CXCL9 and CXCL10 but exhibits distinct receptor-binding affinity and functional specificity due to variations in its N-terminal domain. This protein is implicated in inflammatory diseases, autoimmune disorders, and cancer, where it modulates leukocyte trafficking, angiogenesis, and tumor microenvironment dynamics.
Recombinant CXCL11 is produced using heterologous expression systems, such as *E. coli* or mammalian cells, followed by purification to ensure high specificity and bioactivity. Its production enables detailed study of CXCL11’s role in pathological processes, including its dual pro- and anti-tumor effects. In cancer, CXCL11 expression correlates with immune infiltration and patient prognosis, making it a potential therapeutic target or biomarker. Additionally, recombinant CXCL11 facilitates drug discovery, serving as a tool for screening antagonists or agonists targeting the CXCR3 pathway in conditions like psoriasis, multiple sclerosis, and rheumatoid arthritis.
The development of recombinant CXCL11 has advanced research into its post-translational modifications, receptor signaling mechanisms, and cross-talk with other chemokines. Its applications extend to in vitro and in vivo models to explore immune regulation and tissue-specific responses. Despite challenges in reconciling its context-dependent roles, recombinant CXCL11 remains critical for elucidating chemokine biology and developing targeted immunotherapies. Its standardized production ensures reproducibility in studies, underscoring its value in both basic research and clinical translation.
×
